Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 25, 2023
Event: Completion of the acquisition of Cyclica Inc. pursuant to a Share Purchase Agreement dated May 8, 2023.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain periodic financial statements (e.g., revenue, profit, cash flow, or margins). The filing details the consideration for the acquisition of Cyclica Inc.:
- Equity Consideration: Up to approximately 5.7 million shares of Recursion Class A common stock.
- Cash Consideration: Up to approximately $3.9 million (including payments to unaccredited investors in lieu of shares).
- Assumed Liabilities: Assumption of Cyclica's outstanding options exercisable for up to approximately 0.8 million shares of Class A common stock.
The filing text does not provide a clear value for the company's current debt, liquidity, or operating results.
Material Changes
The primary material change reported is the expansion of the company's portfolio through the acquisition of 100% of the outstanding equity securities of Cyclica Inc. This transaction alters the company's capital structure through the issuance of new shares and the assumption of existing options.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful closing of the previously disclosed acquisition. No specific forward-looking guidance regarding revenue or earnings is provided in this document.
Risks and Contingencies: The filing notes that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the final number of shares issued and cash paid upon final settlement of the Cyclica acquisition.
- Review the impact of the 5.7 million new shares and 0.8 million assumed options on existing shareholder dilution.
- Confirm the integration timeline and strategic rationale for Cyclica in subsequent earnings releases or investor presentations.
- Check for any updated pro forma financial statements in future filings (e.g., 10-Q or 10-K) reflecting the acquisition.